Lipoprotein(a) Does Not Correlate with Hypertensive Mediated Organ Damage and Subsequent Cardiovascular Events in a Primary Prevention Cohort.

IF 2.9 Q2 PERIPHERAL VASCULAR DISEASE
Chiara Tognola, Davide Paolo Bernasconi, Paola Rebora, Rita Cristina Myriam Intravaia, Costantino Mancusi, Valeria Visco, Arturo Cesaro, Enrica Golia, Fucile Ilaria, Piera Merlini, Maddalena Ardissino, Elvira Inglese, Romano Danesi, Fabrizio Oliva, Anita Andreano, Magda Rognoni, Antonio Russo, Paolo Calabrò, Nicola De Luca, Cristina Giannattasio, Alessandro Maloberti
{"title":"Lipoprotein(a) Does Not Correlate with Hypertensive Mediated Organ Damage and Subsequent Cardiovascular Events in a Primary Prevention Cohort.","authors":"Chiara Tognola, Davide Paolo Bernasconi, Paola Rebora, Rita Cristina Myriam Intravaia, Costantino Mancusi, Valeria Visco, Arturo Cesaro, Enrica Golia, Fucile Ilaria, Piera Merlini, Maddalena Ardissino, Elvira Inglese, Romano Danesi, Fabrizio Oliva, Anita Andreano, Magda Rognoni, Antonio Russo, Paolo Calabrò, Nicola De Luca, Cristina Giannattasio, Alessandro Maloberti","doi":"10.1007/s40292-026-00781-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Elevated lipoprotein(a) [Lp(a)] levels have been strongly related to cardiovascular (CV) risk. However, its association with Hypertension Mediated Organ Damage (HMOD) and CV events in the primary prevention setting remains unclear.</p><p><strong>Aim: </strong>To evaluate in these patients, the correlation between Lp(a) levels and: (i) heart, vessels and kidney HMOD and; (ii) CV events and all-cause mortality in a primary prevention setting.</p><p><strong>Methods: </strong>747 low CV risk subjects were recruited between 2009 and 2014. HMOD was assessed through Pulse Wave Velocity, carotid Intima-Media Thickness (IMT), presence of carotid plaques, Left Ventricular Hypertrophy (LVH) and Ejection Fraction and glomerular filtration rate. All-cause mortality and CV events up to 2021 were retrieved by electronic health records, for a median follow-up time of 10 years (I-III quartiles 9.6-11.1).</p><p><strong>Results: </strong>Mean age was 50.8 ± 13.0 years and 63.5% of the subjects were men. The prevalence of hypertension was 37.9%, dyslipidemia 67.2%, smoking 17.8%, and diabetes mellitus 8.7%. Median Lp(a) value was 17 mg/dL (5.9-56.0), and 26.5% of patients had values above 50 mg/dL. Regarding HMOD, 10.3% subjects had arterial stiffness, 7.2% increased IMT, 19.8% carotid plaques while only 0.7% had LVH. No significant correlation was found between Lp(a) levels and indices of subclinical HMOD. Furthermore, no relationship was found between CV events and all-cause mortality and Lp(a) levels.</p><p><strong>Conclusions: </strong>In this primary prevention cohort, elevated Lp(a) levels were not associated with significant structural damage to the heart, carotid arteries, or increased aortic stiffness and were not associated with CV events and all-cause mortality.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"425-437"},"PeriodicalIF":2.9000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13283175/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-026-00781-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Elevated lipoprotein(a) [Lp(a)] levels have been strongly related to cardiovascular (CV) risk. However, its association with Hypertension Mediated Organ Damage (HMOD) and CV events in the primary prevention setting remains unclear.

Aim: To evaluate in these patients, the correlation between Lp(a) levels and: (i) heart, vessels and kidney HMOD and; (ii) CV events and all-cause mortality in a primary prevention setting.

Methods: 747 low CV risk subjects were recruited between 2009 and 2014. HMOD was assessed through Pulse Wave Velocity, carotid Intima-Media Thickness (IMT), presence of carotid plaques, Left Ventricular Hypertrophy (LVH) and Ejection Fraction and glomerular filtration rate. All-cause mortality and CV events up to 2021 were retrieved by electronic health records, for a median follow-up time of 10 years (I-III quartiles 9.6-11.1).

Results: Mean age was 50.8 ± 13.0 years and 63.5% of the subjects were men. The prevalence of hypertension was 37.9%, dyslipidemia 67.2%, smoking 17.8%, and diabetes mellitus 8.7%. Median Lp(a) value was 17 mg/dL (5.9-56.0), and 26.5% of patients had values above 50 mg/dL. Regarding HMOD, 10.3% subjects had arterial stiffness, 7.2% increased IMT, 19.8% carotid plaques while only 0.7% had LVH. No significant correlation was found between Lp(a) levels and indices of subclinical HMOD. Furthermore, no relationship was found between CV events and all-cause mortality and Lp(a) levels.

Conclusions: In this primary prevention cohort, elevated Lp(a) levels were not associated with significant structural damage to the heart, carotid arteries, or increased aortic stiffness and were not associated with CV events and all-cause mortality.

在一级预防队列中,脂蛋白(a)与高血压介导的器官损伤和随后的心血管事件无关。
简介:脂蛋白(a) [Lp(a)]水平升高与心血管(CV)风险密切相关。然而,其与高血压介导的器官损害(HMOD)和心血管事件在一级预防设置的关系尚不清楚。目的:评价这些患者Lp(a)水平与:(1)心脏、血管和肾脏HMOD和;(ii)初级预防环境中的心血管事件和全因死亡率。方法:2009 - 2014年间招募747名低CV风险受试者。通过脉搏波速度、颈动脉内膜-中膜厚度(IMT)、颈动脉斑块的存在、左心室肥厚(LVH)、射血分数和肾小球滤过率来评估HMOD。通过电子健康记录检索截至2021年的全因死亡率和CV事件,中位随访时间为10年(I-III四分位数为9.6-11.1)。结果:平均年龄50.8±13.0岁,男性占63.5%。高血压37.9%,血脂异常67.2%,吸烟17.8%,糖尿病8.7%。中位Lp(a)值为17 mg/dL(5.9-56.0), 26.5%的患者值高于50 mg/dL。在HMOD方面,10.3%的受试者有动脉僵硬,7.2%的受试者有IMT增加,19.8%的受试者有颈动脉斑块,只有0.7%的受试者有LVH。Lp(a)水平与亚临床HMOD指标无显著相关性。此外,没有发现CV事件与全因死亡率和Lp(a)水平之间的关系。结论:在这个一级预防队列中,Lp(a)水平升高与心脏、颈动脉的显著结构性损伤或主动脉僵硬增加无关,也与CV事件和全因死亡率无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
3.30%
发文量
57
期刊介绍: High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes:   Invited ''State of the Art'' reviews.  Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书